Close Menu

Christopher Aston, who penned the first installment of GT’s new monthly RNAi News column (p. 48), grew up in the UK and earned his doctorate from Oxford in molecular biology before moving to the US to take a postdoc post at Rockefeller University. He says he promptly fell in love with New York City, and now holds an adjunct faculty appointment at New York University Medical Center. He has also written for the IEEE Spectrum on bioterrorism and for Nature Genetics about microarrays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.